


PHARMACEUTICAL 2022

NightHawk Biosciences Inc. Rank 86 of 466









PHARMACEUTICAL 2022





NightHawk Biosciences Inc. Rank 86 of 466

The relative strengths and weaknesses of NightHawk Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NightHawk Biosciences Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 47% points. The greatest weakness of NightHawk Biosciences Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 243%, being 165% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	99,331
Cost of Goods Sold	0
Intangible Assets	3,500
Liabilities, Current	4,721
Liabilities, Non-Current	1,149
Other Assets	15,971
Other Compr. Net Income	427
Other Expenses	1,736
Other Liabilities	3,058
Other Net Income	-128
Other Revenues	2,113
Property and Equipment	2,158
Research and Development	18,821
Selling, General and Administrative Expense	16,828

Output Variable	Value in 1000 USD
Assets	120,961
Liabilities	8,928
Expenses	37,386
Revenues	2,113
Stockholders Equity	112,034
Net Income	-35,401
Comprehensive Net Income	-35,187
Economic Capital Ratio	243%

